Impact of different postoperative adjuvant therapies on the survival of early‐stage cervical cancer patients with one intermediate‐risk factor: A multicenter study of 14 years

Abstract

AbstractObjectiveTo compare survival outcomes of different postoperative adjuvant therapies (PATs) for early‐stage cervical cancer (ECC) patients with one intermediate‐risk pathological factor (IPF).MethodsA total of 2889 patients with stage IA1 to IIA2 cervical cancer were included in this study. Three PAT groups were identified, namely a no adjuvant therapy (NAT) group (n = 773), an adjuvant radiotherapy/chemoradiotherapy (ART) group (n = 1648) and an adjuvant chemotherapy (ACT) group (n = 468). Kaplan–Meier analysis and COX regression analysis were used to compare the overall survival (OS) and disease‐free survival (DFS) among the three groups, before and after propensity score matching (PSM).ResultsThe recurrence and mortality rate rates in the NAT, ART and ACT groups were 9.2%, 8.6%, and 7.9%, respectively (p = 0.737). Kaplan–Meier analysis demonstrated no significant differences in the NAT, ART, and ACT groups in 5‐year OS rates (92.8% vs. 93.6% vs. 94.7%, p = 0.594) and DFS rates (88.7% vs. 89.6% vs. 90.5%, p = 0.772). Post‐hoc tests yielded similar results, with no differences in 5‐year OS and DFS (NAT vs. ART, before and after matching, p > 0.05); (NAT vs. ACT, before and after matching, p > 0.05); and (ACT vs. ART, before and after matching, p > 0.05).ConclusionPostoperative adjuvant radiotherapy, chemoradiotherapy, and chemotherapy are not associated with survival outcomes of ECC patients with one IPF. Considering the side effects and impact on patients' quality of life, the PATs should be carefully considered.